2. Academic Validation
  3. Discovery of indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL)

Discovery of indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL)

  • J Med Chem. 2011 Apr 28;54(8):3103-7. doi: 10.1021/jm1016494.
Chih-Hua Tseng 1,  Ru-Wei Lin,  Yeh-Long Chen,  Gwo-Jaw Wang,  Mei-Ling Ho,  Cherng-Chyi Tzeng
Affiliations

Affiliation

  • 1 Department of Medicinal and Applied Chemistry, College of Life Science, Kaohsiung Medical University, Kaohsiung City, Taiwan. tzengch@kmu.edu.tw
PMID: 21456521 DOI: 10.1021/jm1016494
Abstract

Certain indeno[1,2-c]quinolines were synthesized and evaluated for antiosteoclastogenic activities. Among them, 6,9-dimethoxy-11H-indeno[1,2-c]quinolin-11-one (8a) and 9-methoxy-6-(methylthio)-11H-indeno[1,2-c]quinolin-11-one (16a) inhibited RANKL-induced osteoclast formation in Raw 264.7 cells with an IC(50) of 2.00 and 2.58 μM, respectively. Compound 8a was only weakly active in the inhibition of the RANKL-induced NFAT activation, while 16a was inactive. These results indicated that the antiosteoclastogenic effect of 8a is only partly related while 16a is not related to the suppression of NFAT.

Figures